Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 543

1.

Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma.

Rosen MA, Schnall MD.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):770s-776s. Review.

PMID:
17255308
[PubMed - indexed for MEDLINE]
Free Article
2.

Dynamic contrast-enhanced magnetic resonance imaging of vascular changes induced by sunitinib in papillary renal cell carcinoma xenograft tumors.

Hillman GG, Singh-Gupta V, Zhang H, Al-Bashir AK, Katkuri Y, Li M, Yunker CK, Patel AD, Abrams J, Haacke EM.

Neoplasia. 2009 Sep;11(9):910-20.

PMID:
19724685
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

MR imaging of tumor microcirculation: promise for the new millennium.

Taylor JS, Tofts PS, Port R, Evelhoch JL, Knopp M, Reddick WE, Runge VM, Mayr N.

J Magn Reson Imaging. 1999 Dec;10(6):903-7.

PMID:
10581502
[PubMed - indexed for MEDLINE]
4.

Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging.

Choyke PL, Dwyer AJ, Knopp MV.

J Magn Reson Imaging. 2003 May;17(5):509-20. Review.

PMID:
12720260
[PubMed - indexed for MEDLINE]
5.

Dynamic contrast-enhanced magnetic resonance imaging in oncology.

Knopp MV, Giesel FL, Marcos H, von Tengg-Kobligk H, Choyke P.

Top Magn Reson Imaging. 2001 Aug;12(4):301-8. Review.

PMID:
11687716
[PubMed - indexed for MEDLINE]
6.

Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.

Marzola P, Degrassi A, Calderan L, Farace P, Nicolato E, Crescimanno C, Sandri M, Giusti A, Pesenti E, Terron A, Sbarbati A, Osculati F.

Clin Cancer Res. 2005 Aug 15;11(16):5827-32.

PMID:
16115922
[PubMed - indexed for MEDLINE]
Free Article
7.

Magnetic resonance imaging as a biomarker in renal cell carcinoma.

Pedrosa I, Alsop DC, Rofsky NM.

Cancer. 2009 May 15;115(10 Suppl):2334-45. doi: 10.1002/cncr.24237. Review.

PMID:
19402070
[PubMed - indexed for MEDLINE]
Free Article
8.

AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.

Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW, McShane TM, Lu Y, Brasch RC, Hylton NM.

Magn Reson Imaging. 2007 Apr;25(3):319-27. Epub 2007 Feb 5.

PMID:
17371720
[PubMed - indexed for MEDLINE]
9.

Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.

Flaherty KT, Rosen MA, Heitjan DF, Gallagher ML, Schwartz B, Schnall MD, O'Dwyer PJ.

Cancer Biol Ther. 2008 Apr;7(4):496-501. Epub 2008 Jan 22.

PMID:
18219225
[PubMed - indexed for MEDLINE]
Free Article
10.

Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T.

Muruganandham M, Lupu M, Dyke JP, Matei C, Linn M, Packman K, Kolinsky K, Higgins B, Koutcher JA.

Mol Cancer Ther. 2006 Aug;5(8):1950-7.

PMID:
16928815
[PubMed - indexed for MEDLINE]
Free Article
11.

Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging.

Zwick S, Strecker R, Kiselev V, Gall P, Huppert J, Palmowski M, Lederle W, Woenne EC, Hengerer A, Taupitz M, Semmler W, Kiessling F.

J Magn Reson Imaging. 2009 May;29(5):1125-33. doi: 10.1002/jmri.21710.

PMID:
19388117
[PubMed - indexed for MEDLINE]
12.

Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.

de Bazelaire C, Alsop DC, George D, Pedrosa I, Wang Y, Michaelson MD, Rofsky NM.

Clin Cancer Res. 2008 Sep 1;14(17):5548-54. doi: 10.1158/1078-0432.CCR-08-0417.

PMID:
18765547
[PubMed - indexed for MEDLINE]
Free Article
13.

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.

Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, Stadler WM.

J Clin Oncol. 2008 Oct 1;26(28):4572-8. doi: 10.1200/JCO.2007.15.5655.

PMID:
18824708
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Use of H2(15)O-PET and DCE-MRI to measure tumor blood flow.

de Langen AJ, van den Boogaart VE, Marcus JT, Lubberink M.

Oncologist. 2008 Jun;13(6):631-44. doi: 10.1634/theoncologist.2007-0235. Review.

PMID:
18586918
[PubMed - indexed for MEDLINE]
Free Article
15.

MRI of tumor angiogenesis.

Barrett T, Brechbiel M, Bernardo M, Choyke PL.

J Magn Reson Imaging. 2007 Aug;26(2):235-49. Review.

PMID:
17623889
[PubMed - indexed for MEDLINE]
16.

Noninvasive monitoring of radiotherapy-induced microvascular changes using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in a colorectal tumor model.

Ceelen W, Smeets P, Backes W, Van Damme N, Boterberg T, Demetter P, Bouckenooghe I, De Visschere M, Peeters M, Pattyn P.

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1188-96. Epub 2006 Feb 2.

PMID:
16457965
[PubMed - indexed for MEDLINE]
17.

Dynamic contrast-enhanced magnetic resonance imaging of tumors: preclinical validation of parametric images.

Egeland TA, Simonsen TG, Gaustad JV, Gulliksrud K, Ellingsen C, Rofstad EK.

Radiat Res. 2009 Sep;172(3):339-47. doi: 10.1667/RR1787.1.

PMID:
19708783
[PubMed - indexed for MEDLINE]
18.

In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model.

Marzola P, Degrassi A, Calderan L, Farace P, Crescimanno C, Nicolato E, Giusti A, Pesenti E, Terron A, Sbarbati A, Abrams T, Murray L, Osculati F.

Clin Cancer Res. 2004 Jan 15;10(2):739-50.

PMID:
14760097
[PubMed - indexed for MEDLINE]
Free Article
19.

Correlation between estimates of tumor perfusion from microbubble contrast-enhanced sonography and dynamic contrast-enhanced magnetic resonance imaging.

Yankeelov TE, Niermann KJ, Huamani J, Kim DW, Quarles CC, Fleischer AC, Hallahan DE, Price RR, Gore JC.

J Ultrasound Med. 2006 Apr;25(4):487-97.

PMID:
16567438
[PubMed - indexed for MEDLINE]
Free Article
20.

PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.

Rudin M, McSheehy PM, Allegrini PR, Rausch M, Baumann D, Becquet M, Brecht K, Brueggen J, Ferretti S, Schaeffer F, Schnell C, Wood J.

NMR Biomed. 2005 Aug;18(5):308-21.

PMID:
15918178
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk